Home Cart Sign in  
Chemical Structure| 1227962-62-0 Chemical Structure| 1227962-62-0

Structure of Maritoclax
CAS No.: 1227962-62-0

Chemical Structure| 1227962-62-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Marinopyrrole A is a selective Mcl-1 inhibitor with IC50 of 10.1 μM and proapoptosis properties in some cancer cells.

Synonyms: Marinopyrrole-A; (±)-Marinopyrrole A; Marinopyrrole A

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Maritoclax

CAS No. :1227962-62-0
Formula : C22H12Cl4N2O4
M.W : 510.15
SMILES Code : OC1=CC=CC=C1C(C2=C(N3C(C(C4=CC=CC=C4O)=O)=CC(Cl)=C3Cl)C(Cl)=C(Cl)N2)=O
Synonyms :
Marinopyrrole-A; (±)-Marinopyrrole A; Marinopyrrole A
MDL No. :N/A
InChI Key :QYPJBTMRYKRTFG-UHFFFAOYSA-N
Pubchem ID :24797083

Safety of Maritoclax

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302+H312-H315-H318-H411
Precautionary Statements:P264-P270-P273-P280-P301+P312+P330-P302+P352+P312-P305+P351+P338+P310-P332+P313-P391-P501
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

Target
  • Mcl-1

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 breast cancer cells 500 nM To study the activity of marinopyrrole A in A549 breast cancer cells PMC2769490
HCT-116 cells 10 μM 12 h To study the activity of marinopyrrole A in HCT-116 cells and its binding to actin PMC2769490
SK-Hep1 cells 2 μM 24 h Maritoclax enhanced TRAIL-induced apoptosis, as evidenced by the accumulation of sub-G1 population and PARP cleavage. PMC6278439
A549 cells 2 μM 24 h Maritoclax enhanced TRAIL-induced apoptosis, as evidenced by the accumulation of sub-G1 population and PARP cleavage. PMC6278439
A498 cells 2 μM 24 h Maritoclax enhanced TRAIL-induced apoptosis, as evidenced by the accumulation of sub-G1 population and PARP cleavage. PMC6278439
ACHN cells 2 μM 24 h Maritoclax enhanced TRAIL-induced apoptosis, as evidenced by the accumulation of sub-G1 population and PARP cleavage. PMC6278439
Caki cells 1, 2 μM 24 h Maritoclax enhanced TRAIL-induced apoptosis, as evidenced by the accumulation of sub-G1 population and PARP cleavage. PMC6278439
MRSA 320 nM Evaluate the inhibitory effect of MA-D1 on GlmS enzymatic activity, results showed that MA-D1 can effectively inhibit GlmS activity with an IC50 value of 320 nM. PMC11613329
MDA-MB-468 breast cancer cells 3 μM To evaluate the ability of marinopyrrole derivatives to decrease Mcl-1 levels and induce apoptosis. Results showed that several marinopyrrole derivatives significantly decreased Mcl-1 levels and induced caspase 3 activation. PMC4445146
HL60/VCR cells 1 μM 48 h Maritoclax markedly enhances the efficacy of ABT-737 against HL60/VCR cells by 600-fold at 1 μM PMC3323047
Raji cells 2.5 μM 24 h Maritoclax markedly enhances the efficacy of ABT-737 against Raji cells by 2000-fold at 2.5 μM PMC3323047
K562 cells 1–2 μM 24 h Maritoclax markedly enhances the efficacy of ABT-737 against K562 cells by 60-fold at 1–2 μM PMC3323047

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice MRSA infection model Intraperitoneal injection 0.5 and 1 mg/kg #VALUE! Evaluate the antibacterial efficacy of MA-D1 in MRSA-infected mouse models, results showed that MA-D1 significantly reduced bacterial load and rescued infected mice. PMC11613329

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.96mL

0.39mL

0.20mL

9.80mL

1.96mL

0.98mL

19.60mL

3.92mL

1.96mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories